Livagen
Liver bioregulator peptide from the Khavinson series. Short peptide (2-4 amino acids) that targets specific tissue for gene expression regulation and organ health optimization.
Research Status
Limited Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Mild redness, swelling, or itching at the injection site may occur, particularly with repeated injections at the same site. Rotate injection sites to minimize this risk. Reactions typically resolve within 1-2 hours.
Localized urticaria or rash at the injection site may occur in individuals with sensitivity to bovine peptides or excipients. Discontinue use and consult a healthcare provider if this occurs.
Anaphylaxis or severe allergic reaction is extremely rare but possible. Symptoms include difficulty breathing, facial swelling, or severe rash. Seek immediate medical attention if these occur. Individuals with known bovine protein allergies should avoid this peptide.
Mild nausea, stomach discomfort, or changes in appetite may occur with sublingual administration. Taking the peptide with food or switching to subcutaneous injection may reduce symptoms.
Mild headache may occur in the first few days of use, particularly with 2x daily dosing. This typically resolves as the body adjusts. Ensure adequate hydration.
Transient dizziness may occur shortly after injection. Sit or lie down if this occurs. Ensure you are well-hydrated and have eaten before injection.
Repeated injections at the same site may cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Strict site rotation (at least 1 inch between injection points) prevents this complication. If lipodystrophy develops, discontinue injections at that site for 4-6 weeks.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 10-20 mcg |
| Frequency | 1-2x daily |
| Timing | Morning and/or evening, sublingual or subcutaneous |
| Route | Subcutaneous |
Khavinson bioregulator peptide. Start at 10 mcg daily; may increase to 20 mcg split into 2 daily doses. Limited Western clinical trial data; primarily studied in Russian and Eastern European populations. For research purposes only.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
Livagen is a short peptide bioregulator derived from bovine liver tissue that is believed to act as a tissue-specific signaling molecule. It may regulate gene expression in hepatocytes through receptor-mediated pathways, promoting the synthesis of liver-specific proteins, enhancing detoxification enzyme activity, and supporting cellular regeneration and antioxidant defense mechanisms. The peptide is thought to work through epigenetic and post-transcriptional regulation rather than direct enzymatic activity.
Hepatocyte Gene Expression Regulation
Livagen may bind to specific cell surface receptors on hepatocytes, triggering intracellular signaling cascades that upregulate the expression of genes encoding detoxification enzymes (cytochrome P450 family), antioxidant proteins (superoxide dismutase, catalase), and metabolic enzymes involved in lipid and carbohydrate metabolism.
Tissue-Specific Protein Synthesis
The peptide may enhance ribosomal translation of liver-specific proteins, including plasma proteins (albumin, clotting factors), acute-phase reactants, and enzymes involved in bile acid synthesis and cholesterol metabolism.
Cellular Regeneration and Apoptosis Regulation
Livagen may promote hepatocyte proliferation and survival by modulating growth factor signaling pathways and inhibiting apoptosis in damaged or aging liver cells, supporting tissue repair and regeneration.
Antioxidant Defense Enhancement
The peptide may upregulate the expression of antioxidant enzymes and glutathione synthesis pathways, reducing oxidative stress and protecting hepatocytes from damage caused by xenobiotics, alcohol, or metabolic byproducts.
- Livagen is a short peptide (2-4 amino acids) derived from bovine liver tissue, part of the Khavinson bioregulator series
- Bioregulators are thought to act as tissue-specific signaling molecules that regulate gene expression rather than as direct enzyme inhibitors or activators
- The exact amino acid sequence and molecular mechanism remain proprietary and are not fully disclosed in peer-reviewed literature
- Most evidence for Livagen's efficacy comes from Russian and Eastern European clinical studies; limited Western clinical trial data is available
- The peptide is believed to work through receptor-mediated pathways and epigenetic mechanisms rather than through direct enzymatic activity
Track your Livagen research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Livagen is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.